BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Here's a look at 100 experimental therapies in late-stage clinical trials.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
A race has emerged in a new disease space estimated to be worth billions of dollars.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs
You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.
Only one new osteoporosis drug has been approved over the last six years.
A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.
Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals
Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages
GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center
Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt
A trial studying Keytruda met its endpoint in first-line lung cancer patients.
A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs
Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.
Competition among new breast cancer drugs, an immunotherapy contender, and pricing discussions headline one of the biggest cancer conferences of the year.
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
- BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
- Five things for pharma marketers to know: Wednesday, December 7, 2016
- Matt Brown leaves Guidemark Health after merger falls through
- Five things for pharma marketers to know: Monday, December 5, 2016
- GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Women in senior industry roles improve connections with patients, execs say